The Claim
The inhibitor RGX202 binds to the central substrate-binding site of the human creatine transporter (hCRT), making overlapping interactions with the amino acid residues F68, C144, Y148, and F315, which suggests that it acts via a competitive inhibition mechanism to block creatine from binding to the transporter.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called RGX202 sticks to the same spot on a protein that carries creatine in the body, kind of like two keys trying to fit in the same lock — so creatine can't get in, and its movement gets blocked.
See the scientific wording
The inhibitor RGX202 binds to the same central substrate-binding site as creatine in the human creatine transporter (hCRT), engaging overlapping contacts with residues F68, C144, Y148, and F315, which suggests a competitive inhibition mechanism that blocks creatine access.
What the research says
1 studyThe study shows that the drug RGX202 sticks to the same spot on the creatine transporter as creatine itself, blocking it from getting in — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.